These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 22841437)
1. Novel anticancer therapeutics targeting telomerase. Ruden M; Puri N Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437 [TBL] [Abstract][Full Text] [Related]
2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Kelland LR Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745 [TBL] [Abstract][Full Text] [Related]
3. Oligonucleotides Targeting Telomeres and Telomerase in Cancer. Schrank Z; Khan N; Osude C; Singh S; Miller RJ; Merrick C; Mabel A; Kuckovic A; Puri N Molecules; 2018 Sep; 23(9):. PubMed ID: 30189661 [TBL] [Abstract][Full Text] [Related]
4. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Rankin AM; Faller DV; Spanjaard RA Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043 [TBL] [Abstract][Full Text] [Related]
5. Telomere maintenance as a target for drug discovery. Sekaran V; Soares J; Jarstfer MB J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596 [TBL] [Abstract][Full Text] [Related]
6. Telomerase: biology and phase I trials. Kelland LR Lancet Oncol; 2001 Feb; 2(2):95-102. PubMed ID: 11905801 [TBL] [Abstract][Full Text] [Related]
7. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Goldkorn A; Blackburn EH Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715 [TBL] [Abstract][Full Text] [Related]
8. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy. Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605 [TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Folini M; Brambilla C; Villa R; Gandellini P; Vignati S; Paduano F; Daidone MG; Zaffaroni N Eur J Cancer; 2005 Mar; 41(4):624-34. PubMed ID: 15737568 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of telomerase limits the growth of human cancer cells. Hahn WC; Stewart SA; Brooks MW; York SG; Eaton E; Kurachi A; Beijersbergen RL; Knoll JH; Meyerson M; Weinberg RA Nat Med; 1999 Oct; 5(10):1164-70. PubMed ID: 10502820 [TBL] [Abstract][Full Text] [Related]
11. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Kelland L Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545 [TBL] [Abstract][Full Text] [Related]
12. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Vonderheide RH Oncogene; 2002 Jan; 21(4):674-9. PubMed ID: 11850795 [TBL] [Abstract][Full Text] [Related]
13. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Relitti N; Saraswati AP; Federico S; Khan T; Brindisi M; Zisterer D; Brogi S; Gemma S; Butini S; Campiani G Curr Top Med Chem; 2020; 20(6):433-457. PubMed ID: 31894749 [TBL] [Abstract][Full Text] [Related]
14. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro. Yang SM; Fang DC; Yang JL; Chen L; Luo YH; Liang GP Eur J Cancer Prev; 2008 Jun; 17(3):209-17. PubMed ID: 18414191 [TBL] [Abstract][Full Text] [Related]
15. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]. Raymond E; Faivre S; Dieras V; Von Hoff D Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365 [TBL] [Abstract][Full Text] [Related]
16. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Saretzki G; Ludwig A; von Zglinicki T; Runnebaum IB Cancer Gene Ther; 2001 Oct; 8(10):827-34. PubMed ID: 11687906 [TBL] [Abstract][Full Text] [Related]
17. Telomerase-Targeted Cancer Immunotherapy. Mizukoshi E; Kaneko S Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796 [TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics. Zvereva MI; Zatsepin TS; Azhibek DM; Shubernetskaya OS; Shpanchenko OV; Dontsova OA Biochemistry (Mosc); 2015 Mar; 80(3):251-9. PubMed ID: 25761680 [TBL] [Abstract][Full Text] [Related]
19. Telomerase as a therapeutic target for malignant gliomas. Komata T; Kanzawa T; Kondo Y; Kondo S Oncogene; 2002 Jan; 21(4):656-63. PubMed ID: 11850793 [TBL] [Abstract][Full Text] [Related]
20. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors. Liu M; Wang RF; Zhang CL; Yan P; Yu MM; Di LJ; Liu HJ; Guo FQ J Nucl Med; 2007 Dec; 48(12):2028-36. PubMed ID: 18006621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]